A Phase I/II trial led by researchers at Skåne University Hospital and Lund University reported that transplantation of stem-cell-derived dopamine progenitor cells is feasible and was not linked to serious safety issues through the first year of follow-up. The STEM-PD program is an open-label, multicenter study with eight Parkinson’s patients receiving a cryopreserved, off-the-shelf dopaminergic progenitor product. Results were reported in Nature Medicine, with the investigators concluding the trial supports continued development in larger patient cohorts. The findings are positioned against the broader need in Parkinson’s disease to replace lost dopaminergic signaling rather than only treating symptoms. The readout adds to the momentum in cell-replacement and allogeneic stem cell strategies targeting neurodegenerative disease.